Elotuzumab therapy for relapsed or refractory multiple myeloma

Sagar Lonial; Meletios Athanasios Dimopoulos; Antonio Palumbo; Darrell J White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew R Belch; Donna E Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Rollig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus Fernando San Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth Carl Anderson; Paul G Richardson

doi:10.1056/NEJMoa1505654

Elotuzumab therapy for relapsed or refractory multiple myeloma

Sagar Lonial, Meletios Athanasios Dimopoulos, Antonio Palumbo, Darrell J White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen, Andrew R Belch, Donna E Reece, Meral Beksac, Andrew Spencer, Heather Oakervee, Robert Z Orlowski, Masafumi Taniwaki, Christoph Rollig, Hermann Einsele, Ka Lung WuAnil Singhal, Jesus Fernando San Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth Carl Anderson, Paul G Richardson

Medicine Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

1020 Citations (Scopus)

Abstract

Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68 , as compared with 57 in the control group; at 2 years, the rates were 41 and 27 , respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95 confidence interval, 0.57 to 0.85; P

Original language	English
Pages (from-to)	621 - 631
Number of pages	11
Journal	The New England Journal of Medicine
Volume	373
Issue number	7
DOIs	https://doi.org/10.1056/NEJMoa1505654
Publication status	Published - 2015

Access to Document

10.1056/NEJMoa1505654

Cite this

Lonial, S., Dimopoulos, M. A., Palumbo, A., White, D. J., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M-V., Magen, H., Belch, A. R., Reece, D. E., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Rollig, C., Einsele, H., ... Richardson, P. G. (2015). Elotuzumab therapy for relapsed or refractory multiple myeloma. The New England Journal of Medicine, 373(7), 621 - 631. https://doi.org/10.1056/NEJMoa1505654

@article{7ea05db39b044364b52a249d0be66527,

title = "Elotuzumab therapy for relapsed or refractory multiple myeloma",

abstract = "Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68 , as compared with 57 in the control group; at 2 years, the rates were 41 and 27 , respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95 confidence interval, 0.57 to 0.85; P",

author = "Sagar Lonial and Dimopoulos, {Meletios Athanasios} and Antonio Palumbo and White, {Darrell J} and Sebastian Grosicki and Ivan Spicka and Adam Walter-Croneck and Philippe Moreau and Maria-Victoria Mateos and Hila Magen and Belch, {Andrew R} and Reece, {Donna E} and Meral Beksac and Andrew Spencer and Heather Oakervee and Orlowski, {Robert Z} and Masafumi Taniwaki and Christoph Rollig and Hermann Einsele and Wu, {Ka Lung} and Anil Singhal and {San Miguel}, {Jesus Fernando} and Morio Matsumoto and Jessica Katz and Eric Bleickardt and Valerie Poulart and Anderson, {Kenneth Carl} and Richardson, {Paul G}",

year = "2015",

doi = "10.1056/NEJMoa1505654",

language = "English",

volume = "373",

pages = "621 -- 631",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "7",

}

Lonial, S, Dimopoulos, MA, Palumbo, A, White, DJ, Grosicki, S, Spicka, I, Walter-Croneck, A, Moreau, P, Mateos, M-V, Magen, H, Belch, AR, Reece, DE, Beksac, M, Spencer, A, Oakervee, H, Orlowski, RZ, Taniwaki, M, Rollig, C, Einsele, H, Wu, KL, Singhal, A, San Miguel, JF, Matsumoto, M, Katz, J, Bleickardt, E, Poulart, V, Anderson, KC & Richardson, PG 2015, 'Elotuzumab therapy for relapsed or refractory multiple myeloma', The New England Journal of Medicine, vol. 373, no. 7, pp. 621 - 631. https://doi.org/10.1056/NEJMoa1505654

TY - JOUR

T1 - Elotuzumab therapy for relapsed or refractory multiple myeloma

AU - Lonial, Sagar

AU - Dimopoulos, Meletios Athanasios

AU - Palumbo, Antonio

AU - White, Darrell J

AU - Grosicki, Sebastian

AU - Spicka, Ivan

AU - Walter-Croneck, Adam

AU - Moreau, Philippe

AU - Mateos, Maria-Victoria

AU - Magen, Hila

AU - Belch, Andrew R

AU - Reece, Donna E

AU - Beksac, Meral

AU - Spencer, Andrew

AU - Oakervee, Heather

AU - Orlowski, Robert Z

AU - Taniwaki, Masafumi

AU - Rollig, Christoph

AU - Einsele, Hermann

AU - Wu, Ka Lung

AU - Singhal, Anil

AU - San Miguel, Jesus Fernando

AU - Matsumoto, Morio

AU - Katz, Jessica

AU - Bleickardt, Eric

AU - Poulart, Valerie

AU - Anderson, Kenneth Carl

AU - Richardson, Paul G

PY - 2015

Y1 - 2015

N2 - Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68 , as compared with 57 in the control group; at 2 years, the rates were 41 and 27 , respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95 confidence interval, 0.57 to 0.85; P

AB - Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68 , as compared with 57 in the control group; at 2 years, the rates were 41 and 27 , respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95 confidence interval, 0.57 to 0.85; P

UR - http://www.nejm.org/doi/full/10.1056/NEJMoa1505654

U2 - 10.1056/NEJMoa1505654

DO - 10.1056/NEJMoa1505654

M3 - Article

VL - 373

SP - 621

EP - 631

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

SN - 0028-4793

IS - 7

ER -

Elotuzumab therapy for relapsed or refractory multiple myeloma

Abstract

Access to Document

Other files and links

Cite this